This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology
Journal of Hematology & Oncology Open Access 02 March 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333–339.
Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri MA et al. The effect of KIR Ligand Incompatibility on the outcome of unrelated donor transplantation: a report from the center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. Biol Blood Marrow Transplant 2006; 12: 876–884.
Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102: 814–819.
Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38: 291–297.
Cooley S, McCullar V, Wangen R, Bergemann TL, Spellman S, Weisdorf DJ et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005; 106: 4370–4376.
Huang XJ, Chang YJ, Zhao XY . Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transpl Immunol 2006, doi 10.1016/j.trim.2006.10.002.
Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P et al. Determinants of Antileukemia Effects of Allogeneic NK Cells. J Immunol 2004; 172: 644–650.
Verheyden S, Schots R, Duquet W, Demanet C . A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 2005; 19: 1446–1451.
Acknowledgements
This work was supported by the National Natural Science Foundation of China (Grant no.30470753), program for New Century Excellent Talents in University (NECT-04-0011).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huang, Xj., Zhao, Xy., Liu, Dh. et al. Deleterious effects of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion. Leukemia 21, 848–851 (2007). https://doi.org/10.1038/sj.leu.2404566
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404566
This article is cited by
-
The Role of NK Cells and Their Exosomes in Graft Versus Host Disease and Graft Versus Leukemia
Stem Cell Reviews and Reports (2023)
-
Contemporary haploidentical stem cell transplant strategies in children with hematological malignancies
Bone Marrow Transplantation (2021)
-
The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation
Bone Marrow Transplantation (2020)
-
Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide
Leukemia (2019)
-
The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology
Journal of Hematology & Oncology (2018)